Article

Supplement to enhance blepharospasm therapy now available by prescription only

A medical food (Zytaze, OCuSOFT) designed to provide nutritional support to enhance the effectiveness of injections of onabotulinum toxin A (Botox/Botox Cosmetic, Allergan), abobotulinum toxin A (Dysport, Tercica), and rimabotulinum toxin B (Myobloc, Solstice Neurosciences) in the treatment of blepharospasm, hemifacial spasm, and cosmetic procedures now is available in pharmacies as a prescription-only supplement.

Richmond, TX-A medical food (Zytaze, OCuSOFT) designed to provide nutritional support to enhance the effectiveness of injections of onabotulinum toxin A (Botox/Botox Cosmetic, Allergan), abobotulinum toxin A (Dysport, Tercica), and rimabotulinum toxin B (Myobloc, Solstice Neurosciences) in the treatment of blepharospasm, hemifacial spasm, and cosmetic procedures now is available in pharmacies as a prescription-only supplement. 

Formulated with a proprietary, patent-pending blend of highly bioavailable organic zinc and phytase, the product also has been reported to extend the duration of the injection treatments by almost 25%. It is taken 4 days before and on the day of a planned injection (two capsules per day). 

In the event that the supplement is not available at a local pharmacy, eye-care professionals can inform the pharmacy that it can be ordered directly from a wholesale distributor. The company anticipates increased availability through additional wholesale distributors and pharmacies soon.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
(Image credit: Ophthalmology Times) ASCRS 2025: Gregory Moloney, FRANZO, FRCSC, on rotational stability
Sheng Lim, MD, FRCOphth, discusses the CONCEPT study, which compared standalone cataract surgery to cataract surgery with ECP, at the 2025 ASCRS Annual Meeting.
(Image credit: Ophthalmology Times) ASCRS 2025: Steven J. Dell, MD, reports 24-month outcomes for shape-changing IOL
© 2025 MJH Life Sciences

All rights reserved.